Simple Summary The tumor immune escape mechanisms are key factors in cancer
progression and metastasis. They are an undeniable hurdle for successful cancer treatment …

Cervical cancer is one of the most common gynecological tumors, and the majority of early-
stage cervical cancer patients achieve good recovery through surgical treatment and …

Immune checkpoint blockade has revolutionized the field of oncology, inducing durable anti-
tumour immunity in solid tumours. In patients with advanced prostate cancer …

Despite the success of checkpoint blockade in some cancer patients, there is an unmet need
to improve outcomes. Targeting alternative pathways, such as costimulatory molecules (eg …

Background & Aims Advanced pancreatic ductal adenocarcinoma (PDAC) is resistant to
therapy, including immune checkpoint inhibitors. We evaluated the effects of a neutralizing …

Abstract Purpose: This phase I/IIa study (NCT02737475) evaluated the safety and activity of
BMS-986178, a fully human OX40 agonist IgG1 mAb,±nivolumab and/or ipilimumab in …

Unlike traditional cancer therapies, such as surgery, radiation and chemotherapy that are
typically non-specific, cancer immunotherapy harnesses the high specificity of a patient's …

Cancer stands as one of the prominent global causes of death, with its incidence burden
continuously increasing, leading to a substantial rise in mortality rates. Cancer treatment has …

The first anti-tumour necrosis factor (TNF) monoclonal antibody, infliximab (Remicade),
celebrated its 25th anniversary of FDA approval in 2023. Inhibitors of TNF have since proved …

Background Ivuxolimab (PF-04518600) and utomilumab (PF-05082566) are humanized
agonistic IgG2 monoclonal antibodies against OX40 and 4-1BB, respectively. This first-in …